Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study

Abstract Indacaterol (IND; 150 μg), glycopyrronium (GLY; 50 μg) and mometasone furoate (MF; 160 μg [high-dose ICS] and 80 μg [medium-dose ICS]) have been formulated as a once-daily (o.d.) fixed-dose combination treatment delivered via the Breezhaler® device for the treatment of patients with asthma....

Full description

Bibliographic Details
Main Authors: Henrik Watz, Jens M. Hohlfeld, Dave Singh, Jutta Beier, Zuzana Diamant, Jinming Liu, Shucheng Hua, Khalid Abd-Elaziz, Pascale Pinot, Ieuan Jones, Hanns-Christian Tillmann
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Respiratory Research
Subjects:
Indacaterol
Glycopyrronium
Mometasone Furoate
Asthma
Online Access:http://link.springer.com/article/10.1186/s12931-020-01349-5

Internet

http://link.springer.com/article/10.1186/s12931-020-01349-5

Similar Items